EMA Authorised: Ahzantive (aflibercept) — Formycon AG

View source ↗

Summary

EMA authorised Ahzantive (aflibercept) from Formycon AG for several retinal diseases including wet age-related macular degeneration and diabetic macular edema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetic Macular Edema
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Wet Age-related Macular Degeneration

Drugs mentioned

• AHZANTIVE (AFLIBERCEPT-MRBB)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Retinal Vein Occlusion;Choroidal Neovascularization;Diabetes Complications. MAH: Formycon AG. Decision date: 06/11/2025